Plain-English translation of NCT04331093 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a research study testing whether combining two medications — SHR-1210 and apatinib — can help shrink advanced melanoma before surgery. SHR-1210 works by helping your immune system fight cancer cells, while apatinib works by cutting off the blood supply that tumors need to grow. The study will enroll about 40 people with Stage III or IV melanoma on their hands, feet, or under their nails.
Advanced melanoma in these locations is hard to treat and has poor outcomes. Doctors want to see if giving this medication combination before surgery can shrink tumors more effectively and improve survival chances compared to surgery alone.
You likely qualify if…
You likely don't qualify if…
You would receive the two medications (SHR-1210 and apatinib) before your scheduled surgery. You would likely have multiple clinic visits for treatment, blood tests, and imaging scans to monitor how the tumor is responding. After completing the medication course, you would have your planned surgery to remove the tumor, followed by follow-up visits to check your recovery and monitor for any side effects or cancer recurrence.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Di Wu
Enrollment target
~40 participants
Started
March 2021
Primary completion
December 2024
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in May 2021.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Di Wu, MD
Di Wu
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.